SuperworthENDRA Life Sciences EPS NDRA
Diluted earnings per share by quarter and over the last twelve months, from 2016.
- Last 12 months, to Jun 30, 2026
- −$5.99
- Latest quarter, Q2 FY26
- $0.06
- Fiscal year 2025
- −$8.53
ENDRA Life Sciences' earnings per share was −$5.99 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was $0.06.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$8.53 | n/a |
| FY2024 | −$609.83 | n/a |
| FY2023 | −$2904.15 | n/a |
| FY2022 | −$8225.00 | n/a |
| FY2019 | −$80850.00 | n/a |
| FY2018 | −$79450.00 | n/a |
| FY2017 | −$85400.00 | n/a |
| FY2016 | −$134050.00 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.06 | n/a | −$5.99 | |
| Q1 FY26 | −$1.09 | n/a | −$7.76 | |
| Q4 FY25 | −$2.86 | n/a | −$8.53 | |
| Q3 FY25 | −$2.10 | n/a | −$13.39 | |
| Q2 FY25 | −$1.71 | n/a | −$20.83 | |
| Q1 FY25 | −$1.86 | n/a | −$162.11 | |
| Q4 FY24 | −$7.72 | n/a | −$609.83 | |
| Q3 FY24 | −$9.54 | n/a | −$1125.55 | |
| Q2 FY24 | −$142.99 | n/a | −$1116.72 | |
| Q1 FY24 | −$449.58 | n/a | −$1726.23 | |
| Q4 FY23 | −$523.44 | n/a | −$2904.15 | |
| Q3 FY23 | −$0.71 | n/a | −$4200.71 |
Against its peers
Companies in Healthcare nearest ENDRA Life Sciences' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| NDRAENDRA Life Sciences | −$5.99 | |
| NEPHNephros | $0.16 | +33% a year |
| ATNMActinium Pharmaceuticals | $0.36 | |
| APTAlpha Pro Tech | $0.41 | +24% a year |
| SPROSpero Therapeutics | $0.11 | |
| Peer median | $0.26 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on ENDRA Life Sciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.